Creating a new type of DNA vaccine for better immune responses
Official title: MANUFACTURE OF PLASMID DNA DRUG SUBSTANCE AND DRUG PRODUCT
Funded at Midwest Research Institute · NIH-11219072 · Data updated 2026-11-12
This study is testing a new type of vaccine made from DNA that could help boost your immune system against different diseases, and it's designed to be safe and effective for people like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwest Research Institute NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | September 25, 2024 |
| Project end | September 24, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,524,929 |
| NIH project number | 75N91023D00010-0-759102400002-1 |
| Project ID | NIH-11219072 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals seeking new vaccine options for various diseases, particularly those that may benefit from a multi-antigen approach.
✕Less likely to help
Patients who are not interested in vaccination or those with contraindications to DNA vaccines may not receive benefit from this research.
What this research studies
This research focuses on the manufacturing of a multi-antigen plasmid DNA vaccine, which aims to enhance the immune response against various diseases. The process involves generating working cell banks, purifying plasmids, and verifying their integrity using next-generation sequencing. The vaccine is formulated in a specific buffer system to ensure its effectiveness before being prepared for human use under strict manufacturing guidelines. Patients may benefit from this innovative approach to vaccination that could lead to more effective treatments.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines that provide better protection against diseases.
How similar studies have gone: Other research has shown promise in the development of DNA vaccines, indicating that this approach has potential for success.
Where this research is happening
-
Midwest Research Institute
Kansas City, United States Active
Researchers
- Principal investigator: Ginther, Rachel — Midwest Research Institute
- Study coordinator: Ginther, Rachel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.